Erythropoietin in the clinical trials of the cardiac disease, what is and what is not

Mohamad Masoud Majidi Tehrani; Mahnoosh Foroughi

doi:10.22037/jcma.v4i4.29156

Journal of Cellular & Molecular Anesthesia

Current Issue All Issues Accepted Manuscripts Search

Journal Information Editors & Boards Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Reviewer and AE Registration Form New Publisher Announcement Support Contact Us

APC

Authors Guide Submit Manuscript

https://doi.org/10.22037/jcma.v4i4.29156

Erythropoietin in the clinical trials of the cardiac disease, what is and what is not

Author(s):

Mohamad Masoud Majidi Tehrani^1,*,

Mahnoosh Foroughi

²

1Assistant Professor of Cardiovascular Surgery, Department of Cardiovascular Surgery, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2Department of Cardiovascular Surgery, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Journal of Cellular & Molecular Anesthesia:Vol. 4, issue 4; e150180

Published online:Mar 24, 2020

Article type:Review

How to Cite:Majidi Tehrani MM, Foroughi M. Erythropoietin in the clinical trials of the cardiac disease, what is and what is not. J Cell Mol Anesth. 2019;4(4):e150180. doi: https://doi.org/10.22037/jcma.v4i4.29156

Abstract

Erythropoietin (Epo) is the main erythropoiesis hormone, activate the progenitor red blood cells through proliferation, differentiation and maturation of red blood cells. However, it's another receptor in other tissues, including heart and endothelium, confirm its pluripotent activities. A numerous preclinical studies have shown Epo would be cardioprotective against ischemic events, reperfusion injury and apoptosis. The results of Epo in clinical studies were inconclusive with even associated increased risk of adverse outcomes. In this article, a comprehensive review of the Epo effects is evaluated in the coronary artery disease, cardiac surgery, heart failure and its safety through the results of the most recent clinical trials related to Epo in the cardiovascular disease. The analysis of the available clinical trials demonstrates the most determining factors; Epo dose and administration time related to myocardial ischemia onset. It seems the low dose Epo treatment has tissue protective effect through its receptors, while the higher doses of Epo stimulates the other Epo receptors responsible for erythropoiesis. The safety of high dose Epo therapy to increase risk of thrombotic complications has been controversial. The erythropoiesis-stimulating agents have been proven to successfully correct hemoglobin levels, reduce the need to blood products after surgery and can improve the clinical outcomes, without an increased thromboembolic risk.

Keywords

Acute myocardial infarction

Cardioprotection

Cardiovascular outcomes

Heart failure

Erythropoietin

Reperfusion injury.

References

1.
References are in the PDF file of the article.

Import into EndNote Import into BibTex

Crossmark

Checking

Share on

Comments

Number of Comments:0

Cited by

Scopus by DOI: 1
Last Update: 2 weeks ago
Scopus by Title: 1
Last Update: 2 weeks ago
Scopus by Title (Ref): 0
Last Update: 2 weeks ago
CrossRef: 1
Last Update: 4 days ago

Metrics

Licensing and reuse information

Ordering Reprints

Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC

Search Relations

Author(s):

Mohamad Masoud Majidi Tehrani:[PubMed][Scholar]
Mahnoosh Foroughi:[PubMed][Scholar]

Outlines

Erythropoietin in the clinical trials of the cardiac disease, what is and what is not

Abstract

References

Crossmark

Checking

Last Update: 2 weeks ago

Last Update: 2 weeks ago

Last Update: 2 weeks ago

Last Update: 4 days ago